KLK3 and prostate neoplasm: ADT has also been accepted as the first-line treatment for prostate tumors that have extended to the lymph nodes, and biochemical recurrence followed by prostate-specific antigen (PSA) resurgence, asymptomatic metastatic and locally advanced disease[3].